Task force #4—how do we select patients for atherosclerosis imaging?

Imaging Subclinical Atherosclerosis: Where Do We Stand?

The age of initiation and the rate of progression of atherosclerosis vary markedly among individuals and have been difficult to predict with traditional cardiovascular risk assessment models. Although these risk models provide good discrimination and calibration in certain populations, cardiovascular disease (CVD) risk may not be accurately estimated in low- and intermediate risk individuals. T...

How do we select high-quality oocytes?

In vitro maturation (IVM) is being increasingly used to treat human infertility, especially as rescue therapy for patients of polycystic ovarian syndrome and ovarian hyperstimulation syndrome. Quality control and the determination of optimal fertilization conditions—important to increase the use of IVM oocytes for embryo production and improve pregnancy success rates—require a detailed understa...

Diagnostic and therapeutic challenges for dermatologists: What shall we do when we don’t know what to do?

What shall we do when we have done everything we could for the diagnosis and treatment of a patient, but were not successful? What shall we do when there is no definite treatment for a patient? What shall we do when we have no diagnosis or treatment for a patient? Some useful suggestions are presented here to get rid of these situations.

How Do We Understand the Coriolis Force?

The Coriolis force, named after French mathematician Gaspard Gustave de Coriolis (1792–1843), has traditionally been derived as a matter of coordinate transformation by an essentially kinematic technique. This has had the consequence that its physical significance for processes in the atmosphere, as well for simple mechanical systems, has not been fully comprehended. A study of Coriolis’s own s...

Do We Know What We Do not Know? A Response to Celine Bonnet